Eleven-year experience with the avidin-biotin pretargeting system in glioblastoma: Toxicity, efficacy and survival

Chiara M. Grana, Marco Chinol, Concetta de Cicco, Mirco Bartolomei, Marta Cremonesi, Lisa Bodei, Paola A. Rocca, Monica Pacifici, Simone Tiberini, Silvia M. Baio, Giovanni Broggi, Stefano Severi, Giovanni Paganelli

Research output: Contribution to journalArticle

Abstract

Background: The 3-step avidin-biotin pretargeting approach is applied in patients with recurrent glioblastoma (GBM), using biotinylated anti-tenascin monoclonal antibody as the first step of pretargeting followed by avidin and 90Ybiotin. Methods: The present study reviews objective response and overall survival rates in 502 glioblastoma patients treated with 3-step radioimmunotherapy in our institute from December 1994 to December 2005. Patients underwent standard treatment before receiving Pretargeted Antibody-Guided Radionuclide Therapy with 90Y-biotin (PAGRIT ®). Results: Of the 502 patients, 272 (54%) were evaluable for response and 375 (75%) for overall survival. 174 patients (64%) continued to progress after PAGRIT ®, 77 (28%) obtained disease stabilization, and 21 (8%) showed objective tumor regression. Survival of the 375 evaluable patients was 98.4% at 6 months, 79.2% at 12 months, 51.7% at 18 months, and 30.7% at 24 months after the first cycle of PAGRIT ®. All 375 received 3-step PAGRIT ® at recurrence of GBM. The median survival time from diagnosis was 19 months. Conclusion: The results from this retrospective analysis suggest that 90Y-biotin PAGRIT ® interferes with the progression of glioblastoma, prolonging survival in a larger number of patients. Our analysis forms the basis for further prospective trials, where radioimmunotherapy, which is known to be more effective in minimal residual disease, could be offered immediately after surgery.

Original languageEnglish
Pages (from-to)14-20
Number of pages7
JournalOpen Nuclear Medicine Journal
Volume4
DOIs
Publication statusPublished - 2012

Fingerprint

Avidin
Glioblastoma
Biotin
Survival
Radioimmunotherapy
Tenascin
Residual Neoplasm
Radioisotopes
Survival Rate
Monoclonal Antibodies
Recurrence
Antibodies
Therapeutics
Neoplasms

Keywords

  • Avidin-biotin
  • Brain tumor
  • Glioblastoma
  • Monoclonal antibodies
  • Pretargeting
  • Radioimmunotherapy
  • Tenascin

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Eleven-year experience with the avidin-biotin pretargeting system in glioblastoma : Toxicity, efficacy and survival. / Grana, Chiara M.; Chinol, Marco; de Cicco, Concetta; Bartolomei, Mirco; Cremonesi, Marta; Bodei, Lisa; Rocca, Paola A.; Pacifici, Monica; Tiberini, Simone; Baio, Silvia M.; Broggi, Giovanni; Severi, Stefano; Paganelli, Giovanni.

In: Open Nuclear Medicine Journal, Vol. 4, 2012, p. 14-20.

Research output: Contribution to journalArticle

Grana, Chiara M. ; Chinol, Marco ; de Cicco, Concetta ; Bartolomei, Mirco ; Cremonesi, Marta ; Bodei, Lisa ; Rocca, Paola A. ; Pacifici, Monica ; Tiberini, Simone ; Baio, Silvia M. ; Broggi, Giovanni ; Severi, Stefano ; Paganelli, Giovanni. / Eleven-year experience with the avidin-biotin pretargeting system in glioblastoma : Toxicity, efficacy and survival. In: Open Nuclear Medicine Journal. 2012 ; Vol. 4. pp. 14-20.
@article{685bc66f18ff48498618fc598c24061e,
title = "Eleven-year experience with the avidin-biotin pretargeting system in glioblastoma: Toxicity, efficacy and survival",
abstract = "Background: The 3-step avidin-biotin pretargeting approach is applied in patients with recurrent glioblastoma (GBM), using biotinylated anti-tenascin monoclonal antibody as the first step of pretargeting followed by avidin and 90Ybiotin. Methods: The present study reviews objective response and overall survival rates in 502 glioblastoma patients treated with 3-step radioimmunotherapy in our institute from December 1994 to December 2005. Patients underwent standard treatment before receiving Pretargeted Antibody-Guided Radionuclide Therapy with 90Y-biotin (PAGRIT {\circledR}). Results: Of the 502 patients, 272 (54{\%}) were evaluable for response and 375 (75{\%}) for overall survival. 174 patients (64{\%}) continued to progress after PAGRIT {\circledR}, 77 (28{\%}) obtained disease stabilization, and 21 (8{\%}) showed objective tumor regression. Survival of the 375 evaluable patients was 98.4{\%} at 6 months, 79.2{\%} at 12 months, 51.7{\%} at 18 months, and 30.7{\%} at 24 months after the first cycle of PAGRIT {\circledR}. All 375 received 3-step PAGRIT {\circledR} at recurrence of GBM. The median survival time from diagnosis was 19 months. Conclusion: The results from this retrospective analysis suggest that 90Y-biotin PAGRIT {\circledR} interferes with the progression of glioblastoma, prolonging survival in a larger number of patients. Our analysis forms the basis for further prospective trials, where radioimmunotherapy, which is known to be more effective in minimal residual disease, could be offered immediately after surgery.",
keywords = "Avidin-biotin, Brain tumor, Glioblastoma, Monoclonal antibodies, Pretargeting, Radioimmunotherapy, Tenascin",
author = "Grana, {Chiara M.} and Marco Chinol and {de Cicco}, Concetta and Mirco Bartolomei and Marta Cremonesi and Lisa Bodei and Rocca, {Paola A.} and Monica Pacifici and Simone Tiberini and Baio, {Silvia M.} and Giovanni Broggi and Stefano Severi and Giovanni Paganelli",
year = "2012",
doi = "10.2174/1876388X01204010014",
language = "English",
volume = "4",
pages = "14--20",
journal = "Open Nuclear Medicine Journal",
issn = "1876-388X",
publisher = "Bentham Science Publishers B.V.",

}

TY - JOUR

T1 - Eleven-year experience with the avidin-biotin pretargeting system in glioblastoma

T2 - Toxicity, efficacy and survival

AU - Grana, Chiara M.

AU - Chinol, Marco

AU - de Cicco, Concetta

AU - Bartolomei, Mirco

AU - Cremonesi, Marta

AU - Bodei, Lisa

AU - Rocca, Paola A.

AU - Pacifici, Monica

AU - Tiberini, Simone

AU - Baio, Silvia M.

AU - Broggi, Giovanni

AU - Severi, Stefano

AU - Paganelli, Giovanni

PY - 2012

Y1 - 2012

N2 - Background: The 3-step avidin-biotin pretargeting approach is applied in patients with recurrent glioblastoma (GBM), using biotinylated anti-tenascin monoclonal antibody as the first step of pretargeting followed by avidin and 90Ybiotin. Methods: The present study reviews objective response and overall survival rates in 502 glioblastoma patients treated with 3-step radioimmunotherapy in our institute from December 1994 to December 2005. Patients underwent standard treatment before receiving Pretargeted Antibody-Guided Radionuclide Therapy with 90Y-biotin (PAGRIT ®). Results: Of the 502 patients, 272 (54%) were evaluable for response and 375 (75%) for overall survival. 174 patients (64%) continued to progress after PAGRIT ®, 77 (28%) obtained disease stabilization, and 21 (8%) showed objective tumor regression. Survival of the 375 evaluable patients was 98.4% at 6 months, 79.2% at 12 months, 51.7% at 18 months, and 30.7% at 24 months after the first cycle of PAGRIT ®. All 375 received 3-step PAGRIT ® at recurrence of GBM. The median survival time from diagnosis was 19 months. Conclusion: The results from this retrospective analysis suggest that 90Y-biotin PAGRIT ® interferes with the progression of glioblastoma, prolonging survival in a larger number of patients. Our analysis forms the basis for further prospective trials, where radioimmunotherapy, which is known to be more effective in minimal residual disease, could be offered immediately after surgery.

AB - Background: The 3-step avidin-biotin pretargeting approach is applied in patients with recurrent glioblastoma (GBM), using biotinylated anti-tenascin monoclonal antibody as the first step of pretargeting followed by avidin and 90Ybiotin. Methods: The present study reviews objective response and overall survival rates in 502 glioblastoma patients treated with 3-step radioimmunotherapy in our institute from December 1994 to December 2005. Patients underwent standard treatment before receiving Pretargeted Antibody-Guided Radionuclide Therapy with 90Y-biotin (PAGRIT ®). Results: Of the 502 patients, 272 (54%) were evaluable for response and 375 (75%) for overall survival. 174 patients (64%) continued to progress after PAGRIT ®, 77 (28%) obtained disease stabilization, and 21 (8%) showed objective tumor regression. Survival of the 375 evaluable patients was 98.4% at 6 months, 79.2% at 12 months, 51.7% at 18 months, and 30.7% at 24 months after the first cycle of PAGRIT ®. All 375 received 3-step PAGRIT ® at recurrence of GBM. The median survival time from diagnosis was 19 months. Conclusion: The results from this retrospective analysis suggest that 90Y-biotin PAGRIT ® interferes with the progression of glioblastoma, prolonging survival in a larger number of patients. Our analysis forms the basis for further prospective trials, where radioimmunotherapy, which is known to be more effective in minimal residual disease, could be offered immediately after surgery.

KW - Avidin-biotin

KW - Brain tumor

KW - Glioblastoma

KW - Monoclonal antibodies

KW - Pretargeting

KW - Radioimmunotherapy

KW - Tenascin

UR - http://www.scopus.com/inward/record.url?scp=84863804992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863804992&partnerID=8YFLogxK

U2 - 10.2174/1876388X01204010014

DO - 10.2174/1876388X01204010014

M3 - Article

AN - SCOPUS:84863804992

VL - 4

SP - 14

EP - 20

JO - Open Nuclear Medicine Journal

JF - Open Nuclear Medicine Journal

SN - 1876-388X

ER -